secwatch.observer — SEC 8-K summary
======================================

Issuer:     CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)
CIK:        0001801170
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001801170-23-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clover Health posts first quarterly Adjusted EBITDA profit of $10M; insurance MCR improves to 77.2%
--------------------------------------------------------------------------------

- Q2 revenue $513.6M; insurance revenue up 17% YoY to $314.4M; net loss $28.8M vs $104.4M loss YoY.
- Insurance MCR improved to 77.2% from 92.1% YoY; non-insurance MCR 99.6% vs 106.0%.
- Adjusted EBITDA profit $10.0M compared to loss of $83.9M in Q2 2022; first quarterly positive.
- FY 2023 guidance improved: insurance MCR 83%-85%, Adjusted EBITDA ($70M)-($120M).
- CEO Andrew Toy cites operational efficiencies and Clover Assistant R&D; CFO confident in FY 2024 EBITDA profitability without new capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1801170/000180117023000059/0001801170-23-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1801170/000180117023000059/clov-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001801170-23-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer